{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:01:45Z","timestamp":1787497305505,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Fibroblast activation protein inhibitor (FAPI) is a novel PET tracer that targets various malignant tumors. Although some studies have demonstrated that\n                      <jats:sup>68<\/jats:sup>\n                      Ga-labeled FAPI PET provides diagnostic images shortly after injection, reports on early-phase imaging using [\n                      <jats:sup>18<\/jats:sup>\n                      F]FAPI-74 are limited. This study evaluated the diagnostic potential of early-phase [\n                      <jats:sup>18<\/jats:sup>\n                      F]FAPI-74 PET\/CT imaging.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The cohort comprised 32 patients who underwent whole-body [\n                      <jats:sup>18<\/jats:sup>\n                      F]FAPI-74 PET\/CT at three time points: 10, 30, and 60\u00a0min after administration. The uptake of [\n                      <jats:sup>18<\/jats:sup>\n                      F]FAPI-74 in normal organs and tumors at each time point was evaluated and compared using standardized uptake value (SUV). The contrast between tumor and background uptake was assessed using tumor-to-blood ratios (TBRs), calculated as the ratio of tumor SUVmax to blood pool SUVmean.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The uptake of [\n                      <jats:sup>18<\/jats:sup>\n                      F]FAPI-74 in most organs gradually decreased, except in the mammary gland and nipple. Moreover, uptake due to the excretion increased over time in the gallbladder, and bile duct. Among the 72 lesions identified across patients, the median SUVmax of the tumors remained relatively stable across the time points (5.00, 5.16, and 5.11 at 10, 30, and 60\u00a0min, respectively), while the median TBRs gradually increased (1.57, 2.24, and 2.94, respectively). Subgroup analysis revealed a similar pattern of increasing median TBRs in primary tumors (2.76, 3.72, and 4.04, respectively), lymph node metastases and peritoneal dissemination (1.67, 2.47, and 3.58, respectively), and lung metastases (0.99, 1.35, and 1.48, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TBRs were highest at 60\u00a0min after administration. However, early-phase imaging was considered useful because of its sufficient diagnostic contrast and low physiological uptake in the biliary system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      UMIN Clinical Trials Registry, UMIN000051687. Registered 22 July 2023,\u00a0\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/center6.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_his_list.cgi?recptno=R000058594\" ext-link-type=\"uri\">https:\/\/center6.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_his_list.cgi?recptno=R000058594<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13550-025-01356-x","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T19:18:00Z","timestamp":1764875880000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Optimizing [18F]FAPI-74 PET\/CT imaging: insights from Early-phase tumor uptake and tissue contrast"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8333-5378","authenticated-orcid":false,"given":"Yuki","family":"Hoda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8728-5130","authenticated-orcid":false,"given":"Yasuhiko","family":"Ikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9686-8901","authenticated-orcid":false,"given":"Go","family":"Akamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7520-0942","authenticated-orcid":false,"given":"Michio","family":"Senda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0955-4272","authenticated-orcid":false,"given":"Tomohiko","family":"Yamane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"issue":"2","key":"1356_CR1","doi-asserted-by":"publisher","first-page":"160","DOI":"10.2967\/jnumed.120.244806","volume":"62","author":"A Altmann","year":"2021","unstructured":"Altmann A, Haberkorn U, Siveke J. The latest developments in imaging of fibroblast activation protein. J Nucl Med. 2021;62(2):160\u20137. https:\/\/doi.org\/10.2967\/jnumed.120.244806.","journal-title":"J Nucl Med"},{"issue":"3","key":"1356_CR2","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","volume":"39","author":"AA Fitzgerald","year":"2020","unstructured":"Fitzgerald AA, Weiner LM. The role of fibroblast activation protein in health and malignancy. Cancer Metastasis Rev. 2020;39(3):783\u2013803. https:\/\/doi.org\/10.1007\/s10555-020-09909-3.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"1356_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2967\/jnumed.124.269002","volume":"66","author":"TA Hope","year":"2025","unstructured":"Hope TA, Calais J, Goenka AH, Haberkorn U, Konijnenberg M, McConathy J, et al. SNMMI procedure standard\/EANM practice guideline for fibroblast activation protein (FAP) PET. J Nucl Med. 2025;66(1):26\u201333. https:\/\/doi.org\/10.2967\/jnumed.124.269002.","journal-title":"J Nucl Med"},{"issue":"2","key":"1356_CR4","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.220749","volume":"306","author":"Y Mori","year":"2023","unstructured":"Mori Y, Dendl K, Cardinale J, Kratochwil C, Giesel FL, Haberkorn U. FAPI PET: fibroblast activation protein inhibitor use in oncologic and nononcologic disease. Radiology. 2023;306(2):e220749. https:\/\/doi.org\/10.1148\/radiol.220749.","journal-title":"Radiology"},{"issue":"9","key":"1356_CR5","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","volume":"59","author":"A Loktev","year":"2018","unstructured":"Loktev A, Lindner T, Mier W, Debus J, Altmann A, J\u00e4ger D, et al. A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med. 2018;59(9):1423\u20139. https:\/\/doi.org\/10.2967\/jnumed.118.210435.","journal-title":"J Nucl Med"},{"issue":"9","key":"1356_CR6","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","volume":"59","author":"T Lindner","year":"2018","unstructured":"Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59(9):1415\u201322. https:\/\/doi.org\/10.2967\/jnumed.118.210443.","journal-title":"J Nucl Med"},{"issue":"10","key":"1356_CR7","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","volume":"60","author":"A Loktev","year":"2019","unstructured":"Loktev A, Lindner T, Burger EM, Altmann A, Giesel F, Kratochwil C, et al. Development of fibroblast activation protein\u2013targeted radiotracers with improved tumor retention. J Nucl Med. 2019;60(10):1421\u20139. https:\/\/doi.org\/10.2967\/jnumed.118.224469.","journal-title":"J Nucl Med"},{"issue":"4","key":"1356_CR8","doi-asserted-by":"publisher","first-page":"618","DOI":"10.2967\/jnumed.122.264941","volume":"64","author":"M Naeimi","year":"2023","unstructured":"Naeimi M, Choyke PL, Dendl K, Mori Y, Staudinger F, Watabe T, et al. Three-time-point PET analysis of <Superscript>68<\/Superscript>Ga-FAPI-46 in a variety of cancers. J Nucl Med. 2023;64(4):618\u201322. https:\/\/doi.org\/10.2967\/jnumed.122.264941.","journal-title":"J Nucl Med"},{"issue":"12","key":"1356_CR9","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2967\/jnumed.122.264069","volume":"63","author":"FM Glatting","year":"2022","unstructured":"Glatting FM, Hoppner J, Liew DP, van Genabith A, Spektor AM, Steinbach L, et al. Repetitive early 68Ga-FAPI PET acquisition comparing 68Ga-FAPI-02, 68Ga-FAPI-46, and 68Ga-FAPI-74: methodologic and diagnostic implications for malignant, inflammatory\/reactive, and degenerative lesions. J Nucl Med. 2022;63(12):1844\u201351. https:\/\/doi.org\/10.2967\/jnumed.122.264069.","journal-title":"J Nucl Med"},{"issue":"21","key":"1356_CR10","doi-asserted-by":"publisher","first-page":"5301","DOI":"10.3390\/cancers14215301","volume":"14","author":"FM Glatting","year":"2022","unstructured":"Glatting FM, Hoppner J, Kauczor HU, Huber PE, Kratochwil C, Giesel FL, et al. Subclass analysis of malignant, inflammatory and degenerative pathologies based on multiple timepoint FAPI-PET acquisitions using FAPI-02, FAPI-46 and FAPI-74. Cancers. 2022;14(21):5301. https:\/\/doi.org\/10.3390\/cancers14215301.","journal-title":"Cancers"},{"key":"1356_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.651005","volume":"11","author":"S Wang","year":"2021","unstructured":"Wang S, Zhou X, Xu X, Ding J, Liu T, Jiang J, et al. Dynamic PET\/CT imaging of 68Ga-FAPI-04 in Chinese subjects. Front Oncol. 2021;11:651005. https:\/\/doi.org\/10.3389\/fonc.2021.651005.","journal-title":"Front Oncol"},{"issue":"10","key":"1356_CR12","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1007\/s00259-021-05266-7","volume":"48","author":"J Ferdinandus","year":"2021","unstructured":"Ferdinandus J, Kessler L, Hirmas N, Trajkovic-Arsic M, Hamacher R, Umutlu L, et al. Equivalent tumor detection for early and late FAPI-46 PET acquisition. Eur J Nucl Med Mol Imaging. 2021;48(10):3221\u20137. https:\/\/doi.org\/10.1007\/s00259-021-05266-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"1356_CR13","doi-asserted-by":"publisher","first-page":"779","DOI":"10.2967\/jnumed.120.253062","volume":"62","author":"M R\u00f6hrich","year":"2021","unstructured":"R\u00f6hrich M, Naumann P, Giesel FL, Choyke PL, Staudinger F, Wefers A, et al. Impact of <Superscript>68<\/Superscript>Ga-FAPI PET\/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas. J Nucl Med. 2021;62(6):779\u201386. https:\/\/doi.org\/10.2967\/jnumed.120.253062.","journal-title":"J Nucl Med"},{"issue":"1","key":"1356_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2967\/jnumed.121.261925","volume":"63","author":"M R\u00f6hrich","year":"2022","unstructured":"R\u00f6hrich M, Leitz D, Glatting FM, Wefers AK, Weinheimer O, Flechsig P, et al. Fibroblast activation protein\u2013specific PET\/CT imaging in fibrotic interstitial lung diseases and lung cancer: a translational exploratory study. J Nucl Med. 2022;63(1):127\u201333. https:\/\/doi.org\/10.2967\/jnumed.121.261925.","journal-title":"J Nucl Med"},{"key":"1356_CR15","doi-asserted-by":"publisher","first-page":"17848","DOI":"10.1038\/s41598-023-43049-2","volume":"13","author":"J Hoppner","year":"2023","unstructured":"Hoppner J, van Genabith L, Hielscher T, Heger U, Sperling L, Colbatzky T, et al. Comparison of early and late 68Ga-FAPI-46-PET in 33 patients with possible recurrence of pancreatic ductal adenocarcinomas. Sci Rep. 2023;13:17848. https:\/\/doi.org\/10.1038\/s41598-023-43049-2.","journal-title":"Sci Rep"},{"issue":"11","key":"1356_CR16","doi-asserted-by":"publisher","first-page":"7877","DOI":"10.1007\/s00330-023-09715-9","volume":"33","author":"Y Mori","year":"2023","unstructured":"Mori Y, Haberkorn U, Giesel FL. 68Ga- or 18F-FAPI PET\/CT\u2014what it can and cannot. Eur Radiol. 2023;33(11):7877\u20138. https:\/\/doi.org\/10.1007\/s00330-023-09715-9.","journal-title":"Eur Radiol"},{"issue":"12","key":"1356_CR17","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.2967\/jnumed.120.242958","volume":"61","author":"J Toms","year":"2020","unstructured":"Toms J, Kogler J, Maschauer S, Daniel C, Schmidkonz C, Kuwert T, et al. Targeting fibroblast activation protein: radiosynthesis and preclinical evaluation of an 18F-labeled FAP inhibitor. J Nucl Med. 2020;61(12):1806\u201313. https:\/\/doi.org\/10.2967\/jnumed.120.242958.","journal-title":"J Nucl Med"},{"key":"1356_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s41181-021-00144-x","volume":"6","author":"T Lindner","year":"2021","unstructured":"Lindner T, Altmann A, Giesel F, Kratochwil C, Kleist C, Kr\u00e4mer S, et al. 18F-labeled tracers targeting fibroblast activation protein. EJNMMI Radiopharm Chem. 2021;6:26. https:\/\/doi.org\/10.1186\/s41181-021-00144-x.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"8","key":"1356_CR19","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.2967\/jnumed.123.265486","volume":"64","author":"T Watabe","year":"2023","unstructured":"Watabe T, Naka S, Tatsumi M, Kamiya T, Kimura T, Shintani Y, et al. Initial evaluation of [ <Superscript>18<\/Superscript>F]FAPI-74 PET for various histopathologically confirmed cancers and benign lesions. J Nucl Med. 2023;64(8):1225\u201331. https:\/\/doi.org\/10.2967\/jnumed.123.265486.","journal-title":"J Nucl Med"},{"issue":"1","key":"1356_CR20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2967\/jnumed.123.266329","volume":"65","author":"W Xu","year":"2024","unstructured":"Xu W, Cai J, Peng T, Meng T, Pang Y, Sun L, et al. Fibroblast activation protein\u2013targeted PET\/CT with <Superscript>18<\/Superscript>F-fibroblast activation protein inhibitor-74 for evaluation of gastrointestinal cancer: comparison with <Superscript>18<\/Superscript>F-FDG PET\/CT. J Nucl Med. 2024;65(1):40\u201351. https:\/\/doi.org\/10.2967\/jnumed.123.266329.","journal-title":"J Nucl Med"},{"issue":"6","key":"1356_CR21","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1007\/s11307-024-01950-w","volume":"26","author":"WG Yun","year":"2024","unstructured":"Yun WG, Gil J, Choi H, Han Y, Jung HS, Cho YJ, et al. Prospective comparison of [18F]FDG and [18F]AIF-FAPI-74 PET\/CT in the evaluation of potentially resectable pancreatic ductal adenocarcinoma. Mol Imaging Biol. 2024;26(6):1068\u201377. https:\/\/doi.org\/10.1007\/s11307-024-01950-w.","journal-title":"Mol Imaging Biol"},{"issue":"6","key":"1356_CR22","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s00259-023-06564-y","volume":"51","author":"Y Mori","year":"2024","unstructured":"Mori Y, Kramer V, Novruzov E, Mamlins E, R\u00f6hrich M, Fern\u00e1ndez R, et al. Initial results with [18F]FAPI-74 PET\/CT in idiopathic pulmonary fibrosis. Eur J Nucl Med Mol Imaging. 2024;51(6):1605\u201311. https:\/\/doi.org\/10.1007\/s00259-023-06564-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"1356_CR23","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1007\/s00259-021-05646-z","volume":"49","author":"K Hu","year":"2022","unstructured":"Hu K, Wang L, Wu H, Huang S, Tian Y, Wang Q, et al. [18F]FAPI-42 PET imaging in cancer patients: optimal acquisition time, biodistribution, and comparison with [68Ga]Ga-FAPI-04. Eur J Nucl Med Mol Imaging. 2022;49(8):2833\u201343. https:\/\/doi.org\/10.1007\/s00259-021-05646-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1356_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s41824-023-00186-1","volume":"7","author":"X Mu","year":"2023","unstructured":"Mu X, Mo B, Qin J, Li Z, Chong W, Zeng Y, et al. Comparative analysis of two timepoints on [18F]FAPI-42 PET\/CT in various cancers. Eur J Hybrid Imaging. 2023;7:27. https:\/\/doi.org\/10.1186\/s41824-023-00186-1.","journal-title":"Eur J Hybrid Imaging"},{"issue":"2","key":"1356_CR25","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2967\/jnumed.120.245084","volume":"62","author":"FL Giesel","year":"2021","unstructured":"Giesel FL, Adeberg S, Syed M, Lindner T, Jim\u00e9nez-Franco LD, Mavriopoulou E, et al. FAPI-74 PET\/CT using either 18F-AlF or cold-kit 68Ga labeling: biodistribution, radiation dosimetry, and tumor delineation in lung cancer patients. J Nucl Med. 2021;62(2):201\u20137. https:\/\/doi.org\/10.2967\/jnumed.120.245084.","journal-title":"J Nucl Med"},{"key":"1356_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s41181-021-00142-z","volume":"6","author":"S Naka","year":"2021","unstructured":"Naka S, Watabe T, Lindner T, Cardinale J, Kurimoto K, Moore M, et al. One-pot and one-step automated radio-synthesis of [18F]AlF-FAPI-74 using a multi purpose synthesizer: a proof-of-concept experiment. EJNMMI Radiopharm Chem. 2021;6:28. https:\/\/doi.org\/10.1186\/s41181-021-00142-z.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"3","key":"1356_CR27","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"1356_CR28","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.cpet.2023.03.005","volume":"18","author":"K Dendl","year":"2023","unstructured":"Dendl K, Koerber SA, Watabe T, Haberkorn U, Giesel FL. Current status of fibroblast activation protein imaging in gynecologic malignancy and breast cancer. PET Clin. 2023;18(3):345\u201351. https:\/\/doi.org\/10.1016\/j.cpet.2023.03.005.","journal-title":"PET Clin"},{"issue":"8","key":"1356_CR29","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s12149-023-01852-x","volume":"37","author":"L Evangelista","year":"2023","unstructured":"Evangelista L, Filippi L, Schillaci O. What radiolabeled FAPI pet can add in breast cancer? A systematic review from literature. Ann Nucl Med. 2023;37(8):442\u201350. https:\/\/doi.org\/10.1007\/s12149-023-01852-x.","journal-title":"Ann Nucl Med"},{"issue":"12","key":"1356_CR30","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1007\/s00259-021-05378-0","volume":"48","author":"K Dendl","year":"2021","unstructured":"Dendl K, Koerber SA, Finck R, Mokoala KMG, Staudinger F, Schillings L, et al. 68Ga-FAPI-PET\/CT in patients with various gynecological malignancies. Eur J Nucl Med Mol Imaging. 2021;48(12):4089\u2013100. https:\/\/doi.org\/10.1007\/s00259-021-05378-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1356_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1464779","volume":"11","author":"J Dai","year":"2024","unstructured":"Dai J, Zhou W, Liu H, Jiang C, Ye H. Impact of fat intake on [18F]AlF-NOTA-FAPI-04 uptake in normal abdominal organs. Front Med. 2024;11:1464779. https:\/\/doi.org\/10.3389\/fmed.2024.1464779.","journal-title":"Front Med"},{"issue":"6","key":"1356_CR32","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1007\/s00259-024-06598-w","volume":"51","author":"A Ohnishi","year":"2024","unstructured":"Ohnishi A, Yamane T, Shimizu K, Sasaki M, Senda M, Matsumoto T, et al. False-positive [18F]FAPI-74 uptake caused by blood retention due to external jugular vein thrombus: pitfall in the early-phase scan. Eur J Nucl Med Mol Imaging. 2024;51(6):1790\u20131. https:\/\/doi.org\/10.1007\/s00259-024-06598-w.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01356-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-025-01356-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01356-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:01:38Z","timestamp":1781622098000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13550-025-01356-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1356"],"URL":"https:\/\/doi.org\/10.1186\/s13550-025-01356-x","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"21 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was registered in the UMIN Clinical Trials Registry (UMIN000051687). This study was approved by the Kobe City Medical Center General Hospital Research Ethics Committee (#23073).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and content participate\u00a0"}},{"value":"Written informed consent was obtained from all participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The precursor of\n                      18\n                      F-FAPI-74 was purchased from SOFIE. Yasuhiko Ikari is an employee of CMIC Co., Ltd. Hiroyuki Nishida is an employee of Micron, Inc. The other authors declare that they have no conflict of interest relevant to this report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}